Get alerts when MIST reports next quarter
Set up alerts — freeMilestone shares fell 20.6% after earnings, as investors likely focused on the gap between launch growth and the company’s need to cut costs: CARDAMYST prescriptions rose 50% quarter over quarter, but Milestone is reducing operating expenses by about 30% and restructuring its commercial organization. The transcript does not provide a revised sales outlook; the cost measures and leadership departures suggest the launch has yet to support the prior operating structure.
See MIST alongside your other holdings
Add to your portfolio — freeTrack Milestone Pharmaceuticals Inc. in your portfolio with real-time analytics, dividend tracking, and more.
View MIST Analysis